UPPSALA, Sweden , March 6, 2026 /PRNewswire/ --Â Orexo AB (Publ.), (STO: ORX)Â (OTCQX: ORXOY)Â today invites investors, analysts and media to attend the company's R&D Day on March 24, 2026. The event...
UPPSALA, Sweden , March 6, 2026 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) , today announces changes to its organizational structure and management team. The changes are a result...
UPPSALA, Sweden , Sept. 5, 2025 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announced positive pharmacokinetic in-vivo data for a powder-based intranasal semaglutide...
The six-month randomized controlled trial (RCT) enrolled 437 participants at 36 sites across the US The study demonstrated no statistically significant...
/PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces the submission of the New Drug Application (NDA) to the US Food and Drug...
/PRNewswire/ -- Orexo AB (Publ.), (STO:ORX) (OTCQX:ORXOY), today announces the company will participate in Pareto Securities' 14th Annual Healthcare...
/PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces that the United States Patent and Trademark Office (USPTO) has granted the first US...
/PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces that Sun Pharmaceutical Industries Limited, Sun Pharma Global FZE, Sun Pharma...
/PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces that the US District Court for the District of New Jersey ruled in favor of Orexo...
/PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces the expected US launch of OX124, a high-dose rescue medication for opioid overdose,...